research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors
The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.
research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
LLLT devices for hair loss need more research to define proper guidelines.
research FDA Reports of Alopecia as an Adverse Event to Isotretinoin
Isotretinoin may cause hair loss, especially in women and young adults.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
research Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
Finasteride use may increase suicidality risk, especially in young men.
research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Bidirectional Barbed Sutures for Wound Closure: Evolution and Applications
Bidirectional barbed sutures are effective and can reduce surgery time, with a low infection rate and potential cost savings despite being more expensive.
research Photobiomodulation therapy for androgenetic alopecia: A clinician’s guide to home-use devices cleared by the Federal Drug Administration
FDA-cleared devices may help treat hair loss, but more research needed; consult dermatologist before use.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
research The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database
Some medications might contribute to male infertility, with finasteride showing a high number of reports.
research Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
research Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
New technologies replicate human skin for testing without animals.
research Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia
Insurance coverage for scalp cooling will make it more accessible to all chemotherapy patients.
research Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
research From Eye Care to Hair Growth: Bimatoprost
Bimatoprost helps with hair growth and eye conditions but can be costly and have side effects.
research What to Look for in Red Light Therapy: A Product Guide Backed by Science
Choose FDA-cleared red light therapy devices and follow guidelines for safe use.
research Alopecia – New building blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia
Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.
research Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?
Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.
research The Impact of Centrifugation Devices and Collection Tubes on Fibrin Characteristics and Growth Factor Release Under High- and Low-Speed Protocols
Low-speed protocols with certified centrifuges and FDA-approved glass tubes are best for effective PRF outcomes.